If you're looking for stocks that can make big moves in a short amount of time, the biotech industry has you covered. There are some drugmaker stocks out there that could shoot higher or tumble lower this spring.

Developing useful new drugs can be an extremely lucrative endeavor but only if they get a green light from government regulators. Both of these companies are waiting for important approval decisions from the U.S. Food and Drug Administration (FDA).

Sarepta Therapeutics (NASDAQ: SRPT) develops and markets treatments for Duchenne muscular dystrophy (DMD). This is a progressive inherited disorder caused by a lack of dystrophin, a structural protein that grows between muscle fibers and keeps them from rubbing against each other.

Continue reading

Source Fool.com